Delivery Of Vaccines Articles & Analysis
24 news found
The development of vaccines against superbugs is an important area of research because vaccines can help prevent infections from occurring in the first place and reduce the need for antibiotics. ...
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. ...
Bio-ink products at Matexcel have been specifically designed for a variety of biomedical applications including embolization, wound healing, drug delivery, vaccines and so on. "Matexcel understands the unique needs of each bioprinting application," explained Johnson, one of the representative speakers from Matexcel. ...
ByMatexcel
By keeping up with the latest advancements in the field, its team of expert scientists possesses a deep knowledge of RNA biology, viral vectors, antigen design, and delivery systems. This expertise allows them to design and develop highly effective and safe mRNA vaccine candidates. ...
The featured vaccine products supplied by Alfa Chemistry are listed as below: Nucleic Acid Delivery ExcipientsNucleotide vaccines, including mRNA vaccines with their intracellular antigen synthesis, have been shown to be potent activators of a cytotoxic immune response. However, the intracellular delivery of mRNA ...
The sublingual COVID-19 vaccine uses sublingual mucosal delivery technology to deliver the vaccine to the mucous membrane. ...
Ocean Biomedical is accelerating development of a uniquely powerful malaria vaccine and several malaria therapeutics that target newly discovered pathways. ...
Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. ...
Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines. The HD-MAP is Vaxxas’ proprietary vaccine ...
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) ...
In a new study, scientists report that they have successfully freeze-dried a liposome-based liquid vaccine formula that could be developed for potential use in COVID-19 vaccines. A vaccine that employs the freeze-dried liposomes is still a long way off. ...
Following months of collaborative development work, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh ...
ByAerogen
The award supports a collaboration between POP BIO and the Texas Biomedical Research Institute (Texas Biomed), with the goal of using POP BIO’s next-generation vaccine delivery platform to generate a novel vaccine that seeks to break the cold-chain requirements, and the resulting costs and challenges associated with the need to maintain the ...
Abera Bioscience AB (“Abera” or “the Company”) continues to improve its vaccine platform in collaboration with researchers at Vrije Universiteit Amsterdam. ...
Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations. ...
Recently, several studies have shown that exosomes express some lipids and cell adhesion molecules and ligands naturally targeting certain types of recipient cells, which suggests that exosomes have natural targeting ability based on donor cells and can act as an efficient tool for targeting delivery. With years of experiences in exosome technology, Creative Biolabs has combined ...
Company’s aerosol drug delivery technology used in Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology1 that mitigates the transmission of patient-generated infectious aerosol ...
ByAerogen
(“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella (“MR”) vaccine. The trial will assess the safety, tolerability and immunogenicity of an MR ...
Once reconstituted, however, the vaccines exhibit very poor thermal stability and rapidly lose effectiveness if not refrigerated. This is an important consideration in low- and middle-income countries (LMIC) where cold-chain issues and access to target populations for vaccinations can be challenging. By eliminating the need for reconstitution and improving ...
A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South Korea, according to a UBNow story. ...